≥ 3 mm -> During manufacturing, graft thickness is measured in the freeze-dried state. The rehydration
process (30 minutes, 0.9 % NaCl) increases the thickness by approx. 20 % (data on file).
Portfolio
0.3–0.8 mm
Item number
Description
Size
GT4001
Epiflex®
10 x 20 mm
GT4002
Epiflex®
10 x 30 mm
GT4004
Epiflex®
15 x 15 mm
GT4005
Epiflex®
15 x 30 mm
GT4006
Epiflex®
20 x 20 mm
GT4007
Epiflex®
20 x 40 mm
GT4010
Epiflex®
30 × 30 mm
GT4011
Epiflex®
40 × 40 mm
GT4012
Epiflex®
30 × 60 mm
GT4013
Epiflex®
40 × 80 mm
GT4016
Epiflex®
50 × 100 mm
GT4020
Epiflex®
80 × 160 mm
GT4021
Epiflex®
60 × 160 mm
GT4023
Epiflex®
80 × 120 mm
GT4026
Epiflex®
100 × 160 mm
GT4027
Epiflex®
100 × 180 mm
GT4030
Epiflex®
120 × 160 mm
GT4031
Epiflex®
120 × 180 mm
GT4033
Epiflex®
140 × 180 mm
≥ 0.8 mm
Item number
Description
Size
GT4051
Epiflex®
10 x 20 mm
GT4052
Epiflex®
10 x 30 mm
GT4053
Epiflex®
10 x 40 mm
GT4054
Epiflex®
15 x 15 mm
GT4055
Epiflex®
15 x 30 mm
GT4056
Epiflex®
20 x 20 mm
GT4057
Epiflex®
20 × 40 mm
GT4060
Epiflex®
30 × 30 mm
GT4061
Epiflex®
40 × 40 mm
GT4062
Epiflex®
30 × 60 mm
GT4063
Epiflex®
40 × 80 mm
GT4064
Epiflex®
40 × 160 mm
GT4065
Epiflex®
50 × 50 mm
GT4066
Epiflex®
50 × 100 mm
GT4067
Epiflex®
60 × 60 mm
GT4068
Epiflex®
60 × 120 mm
GT4070
Epiflex®
80 × 160 mm
GT4077
Epiflex®
100 × 180 mm
GT4079
Epiflex®
120 × 140 mm
GT4081
Epiflex®
120 x 180 mm
GT4083
Epiflex®
140 x 180 mm
GT4084
Epiflex®
160 x 240 mm
≥ 3 mm
Item number
Description
Size
GT4115
Epiflex®
50 x 50 mm (Thickness 3.0–4.3 mm)
GT4165
Epiflex®
50 x 50 mm (Thickness 3.9–5.3 mm)
GT4215
Epiflex®
50 x 50 mm (Thickness > 4.9 mm)
You like to order or get more information about our transplants or our company?
For an order request or more transplants information, please contact us here.
The non-profit German Institute for Cell and Tissue Replacement (DIZG) is a pharmaceutical manufacturer based in Berlin and is one of the largest pharmaceutical and biotechnological non-profit organizations of its kind in Europe.
Optimizing transplant properties, adapting them to ever-changing clinical requirements, identifying new surgical applications for existing transplant types, and developing new transplants are what drive the Research & Development (R&D) team.
In Germany, human cell and tissue transplants of human origin are regulated as medicinal products and/or require approval. This means that their production, biological safety, and clinical application are subject to oversight by German authorities. In DIZG's cleanrooms, all regulatory requirements are strictly followed.
The DIZG is investing in a new production facility for allogeneic devitalized tissue preparations to ensure safe patient care. From the groundbreaking in 2021 to the topping-out ceremony and beyond – discover the progress here.
The tissue donations received by the DIZG originate from a living person or are collected post-mortem, i.e. after death. Under sections 3 and 4 of the German Transplantation Act, tissue removal, like organ removal, is only permitted with the consent of the donor or the relatives of the deceased.
The Tissue Donation department works closely with national and international collection facilities as well as with clinics that participate in living donation programmes. Together they ensure that human transplants are available for upcoming operations.
Bone and soft tissue can be donated after death, i.e. post-mortem. However, according to the provisions of the Transplantation Act § 3 and § 4, the removal of tissue is only permitted with the donor's consent.
The demand for safe human tissue transplants exceeds the supply. The more clinics participate in the DIZG donation programme, the more patients can be supplied with human transplants throughout Germany and Europe. This is why it makes sense to expand the tissue donation programme across the board.
Since its foundation, around 868,000 transplants have been manufactured infection-free.
We support doctors* and surgeons in their day-to-day clinical challenges with our versatile human allografts in form of tendons, menisci, bones and much more.
Since its foundation, around 868,000 transplants have been manufactured infection-free.
The DIZG's transplant portfolio already includes 230 innovative human transplant forms for widespread clinical provision. Discover our comprehensive range!
Autologous keratinocyte transplants are often an indispensable treatment method for extensive skin wounds and severe grade 2b and 3 burns. For more than 20 years, the DIZG has been the only institution in Germany to produce these in the form of sheets of human keratinocytes and a suspension of human keratinocytes.
Our autologous cell cultures are produced to the highest standards in the highest possible cleanroom class A. The cultivation and provision of keratinocytes are subject to strict regulatory requirements, which require the DIZG to maintain a separate cleanroom area just for them.
We offer you a comprehensive service for our autologous cell cultures, starting long before the transplantation. We also assist burn clinics in meeting regulatory requirements.